Drug Trial Radar · NCT03783429
Digoxin Evaluation in Chronic Heart Failure: Investigational Study In Outpatients in the Netherlands
Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
982
Actual
Start
Jul 1, 2020
Primary completion
Nov 13, 2025
Study completion Nov 13, 2025
Sponsor
- Lead sponsor
- University Medical Center GroningenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Disphar International B.V.; Teva Nederland BV; Tiofarma BV; Netherlands Heart Foundation; Werkgroep Cardiologische centra Nederland
- First posted
- Dec 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Digoxin is the oldest, market-authorized drug for heart failure (HF), and very cheap. A large trial with digoxin, the DIG trial, executed in the early nineties revealed a highly significant reduction in HF hospitalizations, but no effect on mortality. A post-hoc analysis of the DIG trial suggests that low serum concentrations of digoxin may not only improve HF hospitalizations but also mortality in chronic HF patients. To confirm these retrospective analyses, a prospective, randomized, placebo-controlled trial is necessary to establish the position of digoxin in the contemporary treatment of HF. Therefore, the investigators examine whether low-level, aiming for serum concentrations 0.5-0.9ng/mL, digoxin is beneficial in HF patients with reduced or mid-range ejection fractions (LVEF \<50%).
Conditions
- Heart Failure
Interventions
DigoxinDrug
Digoxin tablets will be given orally
PlacebosDrug
Placebo tablets will be given orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate whether low-dose digoxin compared to placebo reduces the rate of the composite CV outcomeTime frame: Median of 3 years
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
Noordwest Ziekenhuisgroep
Alkmaar, Netherlands
Zorggroep Twente
Almelo, Netherlands
Meander Medisch Centrum
Amersfoort, Netherlands
BovenIJ Ziekenhuis
Amsterdam, Netherlands
Gelre Ziekenhuizen
Apeldoorn, Netherlands
Rijnstate Ziekenhuis
Arnhem, Netherlands
Rode Kruis Ziekenhuis
Beverwijk, Netherlands
Tergooi
Blaricum, Netherlands
Amphia Ziekenhuis
Breda, Netherlands
Ijsselland Ziekenhuis
Capelle aan den IJssel, Netherlands
Reinier de Graaf Gasthuis
Delft, Netherlands
Deventer Ziekenhuis
Deventer, Netherlands
Van Weel Bethesda
Dirksland, Netherlands
Slingeland Ziekenhuis
Doetinchem, Netherlands
Ziekenhuis Gelderse Vallei
Ede, Netherlands
Scheper Ziekenhuis
Emmen, Netherlands
Admiraal de Ruyter Ziekenhuis
Goes, Netherlands
Beatrix Ziekenhuis
Gorinchem, Netherlands
Groene Hart Ziekenhuis
Gouda, Netherlands
Martini Ziekenhuis
Groningen, Netherlands
University Medical Center Groningen
Groningen, Netherlands
Spaarne Gasthuis
Haarlem, Netherlands
Saxenburgh MC
Hardenberg, Netherlands
Ziekenhuis St Jansdal
Harderwijk, Netherlands
Zuyderland Medisch Centrum
Heerlen, Netherlands
Elkerliek Ziekenhuis
Helmond, Netherlands
Bethesda
Hoogeveen, Netherlands
Medisch Centrum Leeuwarden
Leeuwarden, Netherlands
Alrijne Ziekenhuis
Leiden, Netherlands
Maastricht UMC+
Maastricht, Netherlands
Isala Diaconessenhuis
Meppel, Netherlands
Radboud University Medical Center
Nijmegen, Netherlands
Bravis ziekenhuis
Roosendaal, Netherlands
Erasmus Medisch Centrum
Rotterdam, Netherlands
Franciscus Gasthuis
Rotterdam, Netherlands
Ikazia Ziekenhuis
Rotterdam, Netherlands
Franciscus Vlietland
Schiedam, Netherlands
Antonius Ziekenhuis Sneek
Sneek, Netherlands
Refaja
Stadskanaal, Netherlands
Haaglanden Medisch Centrum
The Hague, Netherlands
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.